SAN CARLOS, Calif., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a
biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocyte (TIL) technology, today
announced that company management will present at two investor conferences in September:
- 2018 H.C. Wainwright Annual Global Investment Conference in New York, NY on Wednesday, September 5, 2018 at
10:50 a.m. ET
- Wells Fargo Securities 2018 Healthcare Conference in Boston, MA on Thursday, September 6, 2018 at 1:55 p.m.
ET
A live audio webcast of both presentations will be available by visiting the Investors section of Iovance
Biotherapeutics' website at http://ir.iovance.com/. A replay of the webcasts will be archived on Iovance Biotherapeutics’
website for 30 days following the presentations.
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on the development of cancer immunotherapy products
for the treatment of various cancers. The company's lead product candidate is an adoptive cell therapy using tumor-infiltrating
lymphocyte (TIL) technology being investigated for the treatment of patients with metastatic melanoma, recurrent and/or metastatic
squamous cell carcinoma of the head and neck, recurrent, metastatic or persistent cervical cancer, and locally advanced or
metastatic non-small cell lung cancer. For more information, please visit http://www.iovance.com.
Investor Relations Contact:
Sarah McCabe
Stern Investor Relations, Inc.
212-362-1200
sarah@sternir.com
Media Contact:
John Capodanno
FTI Consulting
212-850-5705
john.capodanno@fticonsulting.com
